Evidence map›Paper›PMID 30586199›Full record

Trial reportBritish journal of clinical pharmacology2019

Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler.

Dave Singh, Frans van den Berg, Brian Leaker, Massimo Corradi, Sunny Jabbal, Sara Collarini, Valentina Mongelli, Luigi Santoro, Annalisa Piccinno, Sonia Biondaro and 1 more

Open access · bronzeAbstract readEquivalence TrialRandomized Controlled Trial
In one paragraph

Trial report in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Inspiratory Profiles Through Easyhaler Dry Powder Inhaler During Acute Bronchoconstriction.Journal of aerosol medicine and pulmonary drug delivery · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Dave SinghMedicines Evaluation Unit, University of Manchester, Manchester, UK.ORCID 0000-0001-8918-7075
Frans van den BergHammersmith Medicines Research ltd, London, UK.
Brian LeakerRespiratory Clinical Trials ltd, London, UK.
Massimo CorradiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.ORCID 0000-0002-2808-4184
Sunny JabbalScottish Centre for Respiratory Research, Dundee, UK.ORCID 0000-0002-9604-9807
Sara CollariniChiesi Farmaceutici SpA, Parma, Italy.ORCID 0000-0002-8625-3142
Valentina MongelliChiesi Farmaceutici SpA, Parma, Italy.
Luigi SantoroChiesi Farmaceutici SpA, Parma, Italy.
Annalisa PiccinnoChiesi Farmaceutici SpA, Parma, Italy.ORCID 0000-0002-7858-788X
Sonia BiondaroChiesi Farmaceutici SpA, Parma, Italy.
Brian LipworthScottish Centre for Respiratory Research, Dundee, UK.
Chiesi (Italy) · ITScottish Water (United Kingdom) · GBHammersmith Medicines Research · GBRespiratory Clinical Trials · GBUniversity of Manchester · GBUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo demonstrate the noninferiority of extrafine beclomethasone/formoterol fumarate (BDP/FF) dry powder inhaler (DPI) vs. extrafine BDP/FF pressurized metered dose inhaler (pMDI; Foster® 100/6 μg NEXThaler and pMDI, respectively) in the onset of reliever effect after methacholine induced bronchospasm in asthmatic patients, evaluated in terms of forced expiratory volume in 1 s (FEV

methodsSixty-five patients received one inhalation of BDP/FF DPI, BDP/FF pMDI or placebo after methacholine challenge, according to a double-blind, double-dummy, cross-over design. Lung function and Borg dyspnoea score were assessed up to 30 min postdose.

resultsFEV

conclusionsExtrafine Foster® NEXThaler, a flow-independent DPI, is comparable to extrafine Foster® pMDI when administered as reliever therapy after methacholine challenge, thus supporting the maintenance and reliever therapy approach also with Foster® NEXThaler.

Indexed as

Administration, InhalationAdultAnti-Asthmatic AgentsAsthmaBeclomethasoneBronchoconstrictionCross-Over StudiesDouble-Blind MethodDrug CombinationsDry Powder InhalersFemaleFormoterol FumarateHumansMaleMetered Dose InhalersMethacholine ChlorideAnti-Asthmatic AgentsBeclomethasoneDrug CombinationsFormoterol FumarateMethacholine ChloridePlacebosPowdersasthmaClinical Trialsinhalation

Identifiers

PMID30586199
PMCPMC6422816
OpenAlexW2906617958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.